© 2017 Evestra, Inc.

2013

 

February, 18

Evestra’s research work to develop novel mesoprogestins published in the scientific peer review journal Steroids

Evestra’s innovative research work which describes the design, synthesis and biological characterization of novel mesoprogestins (partial agonists) has been published in the prestigious peer review journal Steroids. The publication describes a series of new chemical entities partially fluorinated antiprogestins, their biological properties, and applications in antiproliferative indications such as breast cancer, and gynecological indications such as endometriosis and fibroids.

“Synthesis and biological evaluation  of partially fluorinated antiprogestins and mesoprogestins” Steroids 78 (2013) 255-267

Dr. Klaus Nickisch, the first author on this paper and Evestra’s CSO commented, “The publication of our work in the journal Steroids is an important milestone for Evestra since it demonstrates its unique research capabilities in the hormonal steroid area”

April, 24

Evestra received the next license payment from corporate partner to develop and commercialize its lead product for the rest-of-the-world (ROW) market.  Total payments received in 2013 is $1.3 million

Evestra announced today that its first patent in the antiprogestin area which describes new chemical entities with potential applications in oncology and gynecological indications was allowed by the European Patent Office.

May, 6

Evestra’s second publication which describes novel antiprogestins for the treatment of breast cancer published in the scientific peer review journal Steroids

Evestra’s novel antiprogestins antagonists with potential applications in treating breast cancer published in the peer review journal Steroids. This work describes the synthesis of 17-fluorinated steroids and their cytotoxicity profiles in T47D breast cancer cells when compared to known antiprogestins.

“Synthesis and antiprogestional properties of novel 17-fluorinated steroids.” Steroids 78 (2013) 909-919

Dr. Klaus Nickisch, the first author on this second scientific paper and Evestra’s CSO commented, “These potent novel antiprogestins posses unique potential as useful agents in treating and preventing certain forms of breast cancer”.

June, 12

Evestra pre-term birth grant proposal was selected as a finalist in the Saving Lives at Birth Grand Challenge  sponsored by The Gates Foundation

Evestra announced today that its grant application titled “An Effective, Safe and Convenient Approach to Treat Pre-term Birth” was selected to enter the final round of review for the Saving Lives at Birth Grand Challenge. The Company was invited to present its proposal to the review committee at the end of July in Washington DC.

Dr. Ze’ev Shaked, Evestra’s President and CEO commented “We are very pleased to learn that our efforts in other important gynecology areas such as pre-term birth are being recognized by our peers”.

June, 21

Evestra announces research collaboration with Northwestern University in the area of breast cancer.

Evestra announced today that it entered into research collaboration with Northwestern University in the area of breast cancer prevention. The principal investigator is Professor Seema Khan, M.D. (Bluhm Family Professor of Cancer Research at Northwestern University Feinberg School of Medicine) an accomplished thought leader in the area of breast cancer who has been involved in exploring the use of antiprogestins for breast cancer prevention.

Dr. Klaus Nickisch, Evestra’s CSO commented “We are delighted to initiate this important research collaboration with Professor Khan and her laboratory”. He added, “Evestra’s novel antiprogestins are emerging as some of the most potent agents known and we look forward to this unique opportunity to test our compounds in the preclinical breast cancer models developed by Professor Khan and her team”.